View in EDS

Can interferon-inducible gene expression guide treatment? A prospective study in QuantiFERON-positive uveitis with undetermined cause

Saved in:
Bibliographic Details
Title: Can interferon-inducible gene expression guide treatment? A prospective study in QuantiFERON-positive uveitis with undetermined cause
Authors: Rina La Distia Nora, Mei Riasanti, Ratna Sitompul, Lukman Edwar, Made Susiyanti, Yulia Aziza, Ikhwanuliman Putera, Maria Valentina Wibawa, Ulifna Alfiya Sifyana, Muhammad Zakiy Waliyuddin, Rachel Ethelind, Beti Ernawati Dewi, Heri Wibowo
Source: Taiwan J Ophthalmol
Taiwan Journal of Ophthalmology, Vol 15, Iss 2, Pp 259-269 (2025)
Publisher Information: Ovid Technologies (Wolters Kluwer Health), 2025.
Publication Year: 2025
Subject Terms: Ophthalmology, tuberculosis, precision medicine, antituberculosis therapy, gene expression, uveitis, biomarkers, RE1-994, Original Article (Prospective Cohort Study), interferon-inducible gene expression, quantiferon-tb gold
Description: PURPOSE: The purpose of this study was to evaluate the utility of baseline interferon (IFN)-inducible gene expression as a prognostic biomarker for Anti-tubercular therapy (ATT) response in patients with undetermined cause of uveitis who tested positive for QuantiFERON-TB Gold (QFT-positive uveitis). METHODS: This prospective cohort study included 17 QFT-positive uveitis patients at a tertiary uveitis center in Indonesia. Baseline and week 2 peripheral blood transcripts were evaluated through real time-quantitative polymerase chain reaction to assess the expression of 10 IFN-inducible genes (IRF7, IFIT2, STAT1, IL1B, MyD88, TLR8, FCGR1B, GBP1, UBE2L6, and SERPING1). Patients were stratified into clusters based on gene expression patterns. The primary outcome was complete resolution of uveitis at 6 months. RESULTS: Hierarchical clustering revealed two distinct groups. Patients with higher baseline expression of IFN genes (Cluster 2) were more likely to achieve complete uveitis resolution after ATT compared to those with lower expression levels (Cluster 1) (80% vs. 43%). Using a previously established IFN gene signature score (IGSS) cutoff (≥5.61), 82% of high-scoring patients showed complete resolution, compared to only 33% in the low-scoring group (P = 0.046). However, week 2 gene expression changes did not correlate with treatment response, indicating limited utility in monitoring disease activity or predicting long-term outcomes. CONCLUSION: Baseline, but not week 2, peripheral blood IFN-inducible gene expression may serve as a prognostic biomarker for stratifying QFT-positive uveitis patients through prediction of their response to treatment. Patients with higher baseline IGSS are more likely to require ATT to achieve uveitis resolution at 6-month follow-up.
Document Type: Article
Other literature type
Language: English
ISSN: 2211-5072
2211-5056
DOI: 10.4103/tjo.tjo-d-25-00029
Access URL: https://doaj.org/article/e8a952a1e5c04504b09a6b66162eb9c8
Rights: CC BY NC SA
URL: http://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
Accession Number: edsair.doi.dedup.....0b00a4dfa177ba8b697b4c005a3c5bd5
Database: OpenAIRE
Description
Abstract:PURPOSE: The purpose of this study was to evaluate the utility of baseline interferon (IFN)-inducible gene expression as a prognostic biomarker for Anti-tubercular therapy (ATT) response in patients with undetermined cause of uveitis who tested positive for QuantiFERON-TB Gold (QFT-positive uveitis). METHODS: This prospective cohort study included 17 QFT-positive uveitis patients at a tertiary uveitis center in Indonesia. Baseline and week 2 peripheral blood transcripts were evaluated through real time-quantitative polymerase chain reaction to assess the expression of 10 IFN-inducible genes (IRF7, IFIT2, STAT1, IL1B, MyD88, TLR8, FCGR1B, GBP1, UBE2L6, and SERPING1). Patients were stratified into clusters based on gene expression patterns. The primary outcome was complete resolution of uveitis at 6 months. RESULTS: Hierarchical clustering revealed two distinct groups. Patients with higher baseline expression of IFN genes (Cluster 2) were more likely to achieve complete uveitis resolution after ATT compared to those with lower expression levels (Cluster 1) (80% vs. 43%). Using a previously established IFN gene signature score (IGSS) cutoff (≥5.61), 82% of high-scoring patients showed complete resolution, compared to only 33% in the low-scoring group (P = 0.046). However, week 2 gene expression changes did not correlate with treatment response, indicating limited utility in monitoring disease activity or predicting long-term outcomes. CONCLUSION: Baseline, but not week 2, peripheral blood IFN-inducible gene expression may serve as a prognostic biomarker for stratifying QFT-positive uveitis patients through prediction of their response to treatment. Patients with higher baseline IGSS are more likely to require ATT to achieve uveitis resolution at 6-month follow-up.
ISSN:22115072
22115056
DOI:10.4103/tjo.tjo-d-25-00029